APA
Bourlière M., Rabiega P., Ganne-Carrie N., Serfaty L., Marcellin P., Barthe Y., Thabut D., Guyader D., Hezode C., Picon M., Causse X., Leroy V., Bronowicki J. P., Carrieri P., Riachi G., Rosa I., Attali P., Molina J. M., Bacq Y., Tran A., Grangé J. D., Zoulim F., Fontaine H., Alric L., Bertucci I., Bouvier-Alias M. & Carrat F. (20180813). Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. : The lancet. Gastroenterology & hepatology.
Chicago
Bourlière Marc, Rabiega Pascaline, Ganne-Carrie Nathalie, Serfaty Lawrence, Marcellin Patrick, Barthe Yoann, Thabut Dominique, Guyader Dominique, Hezode Christophe, Picon Magali, Causse Xavier, Leroy Vincent, Bronowicki Jean Pierre, Carrieri Patrizia, Riachi Ghassan, Rosa Isabelle, Attali Pierre, Molina Jean Michel, Bacq Yannick, Tran Albert, Grangé Jean Didier, Zoulim Fabien, Fontaine Hélène, Alric Laurent, Bertucci Inga, Bouvier-Alias Magali and Carrat Fabrice. 20180813. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. : The lancet. Gastroenterology & hepatology.
Harvard
Bourlière M., Rabiega P., Ganne-Carrie N., Serfaty L., Marcellin P., Barthe Y., Thabut D., Guyader D., Hezode C., Picon M., Causse X., Leroy V., Bronowicki J. P., Carrieri P., Riachi G., Rosa I., Attali P., Molina J. M., Bacq Y., Tran A., Grangé J. D., Zoulim F., Fontaine H., Alric L., Bertucci I., Bouvier-Alias M. and Carrat F. (20180813). Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. : The lancet. Gastroenterology & hepatology.
MLA
Bourlière Marc, Rabiega Pascaline, Ganne-Carrie Nathalie, Serfaty Lawrence, Marcellin Patrick, Barthe Yoann, Thabut Dominique, Guyader Dominique, Hezode Christophe, Picon Magali, Causse Xavier, Leroy Vincent, Bronowicki Jean Pierre, Carrieri Patrizia, Riachi Ghassan, Rosa Isabelle, Attali Pierre, Molina Jean Michel, Bacq Yannick, Tran Albert, Grangé Jean Didier, Zoulim Fabien, Fontaine Hélène, Alric Laurent, Bertucci Inga, Bouvier-Alias Magali and Carrat Fabrice. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. : The lancet. Gastroenterology & hepatology. 20180813.